Novavax, Inc. NVAX
10.63
0.03
0.28%
as of 25 Sep
- Market cap
- $1.8B
- P/E
- 0.0×
Follow NVAX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(100.06%) | (117.16%) | 79.70% | 323.66% | |
| 23.63% | 32.17% | (7.52%) | (21.62%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
57.55% | 78.19% | (15.96%) | (51.76%) | |
Average Days of Receivables |
11.72 | 34.58 | 14.27 | 16.53 | |
Free Cash Flow per Share |
(1.19) | (1.56) | (0.59) | (0.26) | |
Free Cash Flow |
(193.10) | (252.05) | (96.79) | (42.20) | |
Capital Expenditures |
185.22 | (7.42) | (5.23) | (5.30) | |
Piotroski F-Score |
5.00 | 5.00 | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(43.83%) | (28.30%) | (9.76%) | (4.49%) | |
Accounts Receivable Turnover |
16.49 | 10.46 | 17.59 | 3.38 | |
Accounts Payable Turnover |
2.41 | 2.21 | 3.57 | 2.41 | |
Inventory Turnover |
7.91 | 7.20 | 8.25 | 8.75 | |
Average Days of Payables |
63.44 | 122.82 | 65.58 | 94.55 | |
Days of Inventory on Hand |
56.29 | 57.69 | 46.67 | 41.25 | |
Tax Rate |
(0.03) | 0.00 | 0.02 | 0.01 | |
Research and Development Expense of Revenue |
34.83% | 30.47% | 58.50% | 82.24% | |
Selling, General and Administrative Expense of Revenue |
18.95% | 14.02% | 23.17% | 29.29% | |
Share Based Compensation of Revenue |
3.62% | 3.21% | 5.61% | 7.81% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(1.11) | (0.56) | 1.04 | 0.15 | |
Depreciation/Fixed assets |
0.71 | 0.62 | 0.53 | 0.47 | |
Capex/Depreciation |
5.29 | (0.27) | (0.23) | (0.30) | |
Revenue per Share |
6.56 | 6.94 | 3.65 | 2.51 | |
Operating CF per Share |
(2.33) | (1.51) | (0.56) | (0.22) | |
Capex per Share |
1.14 | (0.05) | (0.03) | (0.03) | |
Capex to Sales |
(0.17) | 0.01 | 0.01 | 0.01 | |
Net Profit Margin |
32.10% | 39.19% | (14.73%) | (59.87%) |
Columns are period end dates